IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMIS e to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: https://www.dhs.pa.gov/providers/Providers/Pages/PROMIS e-Enrollment.aspx.

PURPOSE:

The purpose of this bulletin is to issue the U.S. Department of Health and Human Services’ Centers for Disease Control and Prevention’s (CDC) Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020.

SCOPE:

This bulletin applies to all providers enrolled in the Medical Assistance (MA) Program who administer immunizations and provide services in the Fee-for-Service and managed care delivery systems.

BACKGROUND/DISCUSSION:

As stated in 55 Pa. Code § 1241.42(2), the Department of Human Services (Department) is authorized to issue immunization guidelines based on recommendations of recognized medical organizations involved in children’s health care. To ensure that children and adolescents enrolled in MA receive immunizations that conform to nationally recognized standards, the Department is updating its immunization guidelines to conform to the Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, UNITED STATES, 2020 (2020 Immunization Schedule).

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at: https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx.
Providers are to follow the attached 2020 Immunization Schedule, which is comprised of three tables and a series of related notes. The three tables are as follows:

- **Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020 (Table 1);**
- **Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who are More than 1 month Behind, United States, 2020 (Table 2);** and
- **Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2020 (Table 3).**

The 2020 Immunization Schedule in conjunction with the Advisory Committee on Immunization Practices (ACIP) includes new or updated guidance for hepatitis A vaccine (HepA) (2); influenza vaccine (3); meningococcal B vaccine (MenB) (2); and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) (4). The 2020 Immunization Schedule and ACIP guidance also include clarification of the recommendations for diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), Haemophilus influenzae type b vaccine (Hib), hepatitis B vaccine (HepB), meningococcal ACWY vaccine (MenACWY), and poliovirus vaccine. See *Morbidity and Mortality Weekly Report* Volume 69, February 7, 2020, which can be found at: https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6905a3-H.pdf.

As explained by ACIP in the *Morbidity and Mortality Weekly Report Volume 69, February 7, 2020*, the overall appearance of the 2020 Immunization Schedule has been updated. These changes are in all portions of the immunization schedule, including the cover page, routine immunization schedule (Table 1), catch-up schedule (Table 2), medical indications for each vaccine (Table 3), and notes with details for each vaccine. The changes identified by ACIP are set forth below:

- **Cover page**
  - The American College of Nurse-Midwives has been added to the list of organizations that approve the child and adolescent immunization schedule.

- **Table 1**
  - **HepA row:** The bar for persons aged 2–18 years has been changed to solid green to denote the recommendation for routine catch-up immunization for all persons in this age group.
  - **HPV row:** An asterisk has been added to the blue bar that appears for children aged 9–10 years to indicate that for this group, the HPV vaccine series can be started at the clinician’s discretion. The text that defines the blue box in the table’s legend has been edited and now reads “Recommended based on shared clinical decision-making or *can be used in this age group.***
  - **Legend:** The text that defines the gray box has been edited and now reads “No recommendation/not applicable.”

- **Table 2**
Meningococcal rows: The letters “ACWY” were added to clarify that these catch-up intervals apply only to MenACWY and not to MenB.

- **Table 3**
  - **HepA row:** All boxes now appear yellow to denote the recommendation for routine vaccination for all persons aged 18 years or younger, including those with the medical indications outlined in the table.
  - **MenACWY row:** The pregnancy box is now yellow, because the meningococcal vaccine may be administered to pregnant women, if indicated.
  - **Legend:** The text that defines the red box has been edited and now reads “Not recommended/contraindicated—vaccine should not be administered.” The text that defines the gray box has been edited and now reads “No recommendation/not applicable.”

- **Vaccine Notes**
  - **DTaP:** To clarify the recommendations for catch-up vaccination, the note has been updated to indicate that dose 5 is not necessary if dose 4 was administered at age 4 years or older AND at least 6 months after dose 3.
  - **Hib:** A bullet has been added to note that catch-up vaccination is not recommended for previously unvaccinated children aged 5 years (60 months) or older who are not at high risk.
  - **HepA:** The note was revised to include the recommendation that all children and adolescents aged 2 through 18 years who have not previously received Hep A should receive catch-up vaccination and complete a 2-dose series.
  - **HepB:** A “Special situations” section has been added which contains information regarding populations for whom revaccination might be recommended. The ACIP HepB recommendations are referenced for detailed revaccination recommendations.
  - **Influenza vaccine:** The note has been updated to reflect the recommendations for the 2019–20 influenza season. The “Routine vaccination” section was reformatted to more clearly outline circumstances under which 1 or 2 doses of influenza vaccine are recommended. In addition, the bullet that outlines circumstances under which live attenuated influenza vaccine (LAIV) should not be used was reformatted into a bulleted list.
  - **MenACWY:** Guidance regarding adolescent vaccination for children who received MenACWY before age 10 years has been added to the note.
  - **MenB:** Booster doses are now recommended for persons aged ≥10 years with complement deficiency, those who use complement inhibitors, persons with asplenia, persons who are microbiologists, and persons determined by public health officials to be at increased risk during an outbreak. The MenB note has been updated to include a link to the detailed recommendations.
  - **Poliovirus vaccination:** Detailed information has been added regarding which oral poliovirus vaccine (OPV) doses may be counted toward the U.S. vaccination requirements.
  - **Tdap:** The note has been updated to allow either Td or Tdap, as an option for decennial tetanus booster doses and catch-up series doses in persons who have previously received Tdap. In addition, the note has been edited to reflect recent
updates to the clinical guidance for children aged 7 through 18 years who received doses of Tdap or DTaP at age 7 through 10 years. A dose of Tdap or DTaP administered at age 10 years may now be counted as the adolescent Tdap booster. A dose of Tdap or DTaP administered at age 7 through 9 years should not be counted as the adolescent dose, and Tdap should be administered at age 11–12 years.

For guidance on immunization recommendations, providers are advised to use the tables and the notes together. The 2020 Immunization Schedule is recommended by ACIP and approved by the CDC, the American Academy of Pediatrics, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, and the American College of Nurse-Midwives.

PROCEDURE:

Providers should carefully review the 2020 Immunization Schedule for detailed information on the appropriate dosages and ages for the administration of vaccines and replace their current immunization schedule with the attached 2020 Immunization Schedule. Additional information is available from the CDC at: https://www.cdc.gov/vaccines/schedules/index.html.

The National Childhood Vaccine Injury Act requires that health care providers provide parents or patients with copies of Vaccine Information Statements before administering each dose of the vaccines listed in the schedule. Additional information is available from the CDC at: http://www.cdc.gov/vaccines/hcp/vis/index.html.

IMMUNIZATION GUIDANCE DURING COVID-19:

The CDC has released interim guidance for Immunization Services during the COVID-19 pandemic. With reduced vaccine administration during the COVID-19 pandemic, unvaccinated or undervaccinated patients are susceptible to preventable illness and communities are at risk for outbreaks. Implementation of strategies to promote adherence to the 2020 Immunization Schedule and ensure catch-up vaccination is important, especially for children. The full guidance is available at: https://www.cdc.gov/vaccines/pandemic-guidance/index.html.

Providers are also to follow guidance issued by the American Academy of Pediatrics regarding the provision of well-child visits during the COVID-19 pandemic. Since the onset of the pandemic, a decrease in well-child visits has resulted in delays in vaccinations, screenings, and referrals. Pediatricians are now providing appropriate elements of well-child visits via telehealth. Pediatricians should identify children who have missed well-child visits and/or recommended vaccinations and work with families to bring children up to date. The full guidance is available at: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/guidance-on-providing-pediatric-well-care-during-covid-19/.

OBSELETE BULLETIN:
This bulletin supersedes MA Bulletin 99-19-01, issued April 22, 2019.

**ATTACHMENT:**

*Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, UNITED STATES, 2020*
Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger

UNITED STATES
2020

Vaccines in the Child and Adolescent Immunization Schedule*

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Abbreviations</th>
<th>Trade names</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria, tetanus, and acellular pertussis vaccine</td>
<td>DTaP</td>
<td>Daptacel®</td>
</tr>
<tr>
<td>Diphtheria, tetanus vaccine</td>
<td>DT</td>
<td>No trade name</td>
</tr>
<tr>
<td>Haemophilus influenzae type b vaccine</td>
<td>Hib (PRP-T)</td>
<td>ActHIB®</td>
</tr>
<tr>
<td></td>
<td>Hib (PRP-OMP)</td>
<td>Hibrix®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PedvaxHIB®</td>
</tr>
<tr>
<td>Hepatitis A vaccine</td>
<td>HepA</td>
<td>Havrix®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vaqta®</td>
</tr>
<tr>
<td>Hepatitis B vaccine</td>
<td>HepB</td>
<td>Engerix-B®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recombivax HB®</td>
</tr>
<tr>
<td>Human papillomavirus vaccine</td>
<td>HPV</td>
<td>Gardasil 9®</td>
</tr>
<tr>
<td>Influenza vaccine (inactivated)</td>
<td>IIV</td>
<td>Multiple</td>
</tr>
<tr>
<td>Influenza vaccine (live, attenuated)</td>
<td>LAIV</td>
<td>FluMist® Quadrivalent</td>
</tr>
<tr>
<td>Measles, mumps, and rubella vaccine</td>
<td>MMR</td>
<td>M-M-R® II</td>
</tr>
<tr>
<td>Meningococcal serogroups A, C, W, Y vaccine</td>
<td>MenACWY-D</td>
<td>Menactra®</td>
</tr>
<tr>
<td></td>
<td>MenACWY-CRM</td>
<td>Menveo®</td>
</tr>
<tr>
<td>Meningococcal serogroup B vaccine</td>
<td>MenB-4C</td>
<td>Bexsero®</td>
</tr>
<tr>
<td></td>
<td>MenB-FHbp</td>
<td>Trumenba®</td>
</tr>
<tr>
<td>Pneumococcal 13-valent conjugate vaccine</td>
<td>PCV13</td>
<td>Prevnar 13®</td>
</tr>
<tr>
<td>Pneumococcal 23-valent polysaccharide vaccine</td>
<td>PPSV23</td>
<td>Pneumovax® 23</td>
</tr>
<tr>
<td>Poliovirus vaccine (inactivated)</td>
<td>IPV</td>
<td>IPOL®</td>
</tr>
<tr>
<td>Rotavirus vaccine</td>
<td>RV1</td>
<td>Rotarix®</td>
</tr>
<tr>
<td></td>
<td>RV5</td>
<td>RotaTeq®</td>
</tr>
<tr>
<td>Tetanus, diphtheria, and acellular pertussis vaccine</td>
<td>Tdap</td>
<td>Adacel® Boostrix®</td>
</tr>
<tr>
<td>Tetanus and diphtheria vaccine</td>
<td>Td</td>
<td>Tenivac® Tdavax™</td>
</tr>
<tr>
<td>Varicella vaccine</td>
<td>VAR</td>
<td>Varivax®</td>
</tr>
</tbody>
</table>

**Combination vaccines (use combination vaccines instead of separate injections when appropriate)**

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Abbreviations</th>
<th>Trade names</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTaP, hepatitis B, and inactivated poliovirus vaccine</td>
<td>DTaP-HepB-IPV</td>
<td>Pediarix®</td>
</tr>
<tr>
<td>DTaP, inactivated poliovirus, and Haemophilus influenzae type b vaccine</td>
<td>DTaP-IPV/Hib</td>
<td>Pentacel®</td>
</tr>
<tr>
<td>DTaP and inactivated poliovirus vaccine</td>
<td>DTaP-IPV</td>
<td>Kinrix®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quadracel®</td>
</tr>
<tr>
<td>Measles, mumps, rubella, and varicella vaccine</td>
<td>MMRV</td>
<td>ProQuad®</td>
</tr>
</tbody>
</table>

*Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

How to use the child/adolescent immunization schedule

1. Determine recommended vaccine by age (Table 1)
2. Determine recommended interval for catch-up vaccination (Table 2)
3. Assess need for additional recommended vaccines by medical condition and other indications (Table 3)
4. Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American Academy of Pediatrics (www.aap.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), and American College of Nurse-Midwives (www.midwife.org).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or 800-822-7967

Download the CDC Vaccine Schedules App for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.

Helpful information

- Complete ACIP recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization: www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Outbreak information (including case identification and outbreak response), see Manual for the Surveillance of Vaccine-Preventable Diseases: www.cdc.gov/vaccines/pubs/surv-manual
Table 1

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2). School entry and adolescent vaccine age groups are shaded in gray.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Birth</th>
<th>1 mo</th>
<th>2 mos</th>
<th>4 mos</th>
<th>6 mos</th>
<th>9 mos</th>
<th>12 mos</th>
<th>15 mos</th>
<th>18 mos</th>
<th>19-23 mos</th>
<th>2-3 yrs</th>
<th>4-6 yrs</th>
<th>7-10 yrs</th>
<th>11-12 yrs</th>
<th>13-15 yrs</th>
<th>16 yrs</th>
<th>17-18 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B (HepB)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td>See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, acellular pertussis (DTaP &lt;7 yrs)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td>3&lt;sup&gt;rd&lt;/sup&gt; dose</td>
<td></td>
<td>← 4&lt;sup&gt;th&lt;/sup&gt; dose →</td>
<td>5&lt;sup&gt;th&lt;/sup&gt; dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b (Hib)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td>See Notes</td>
<td>3&lt;sup&gt;rd&lt;/sup&gt; or 4&lt;sup&gt;th&lt;/sup&gt; dose, See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate (PCV13)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td>3&lt;sup&gt;rd&lt;/sup&gt; dose</td>
<td>← 4&lt;sup&gt;th&lt;/sup&gt; dose →</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b (Hib)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td>See Notes</td>
<td>3&lt;sup&gt;rd&lt;/sup&gt; or 4&lt;sup&gt;th&lt;/sup&gt; dose, See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate (PCV13)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td>3&lt;sup&gt;rd&lt;/sup&gt; dose</td>
<td>← 4&lt;sup&gt;th&lt;/sup&gt; dose →</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus (IPV &lt;18 yrs)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td>3&lt;sup&gt;rd&lt;/sup&gt; dose</td>
<td>← 4&lt;sup&gt;th&lt;/sup&gt; dose →</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (IIV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination 1 or 2 doses</td>
<td>Annual vaccination 1 dose only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (LAIV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination 1 or 2 doses</td>
<td>Annual vaccination 1 dose only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella (VAR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A (HepA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (PPSV23)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Range of recommended ages for all children
- Range of recommended ages for catch-up immunization
- Range of recommended ages for certain high-risk groups
- Recommended based on shared clinical decision-making or
- *can be used in this age group
- No recommendation/not applicable
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Vaccine Minimum Age for Dose 1</th>
<th>Minimum Interval Between Doses</th>
<th>Vaccine Minimum Age for Dose 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
<td>Birth</td>
<td></td>
<td>Dose 1 to Dose 2</td>
<td>Dose 2 to Dose 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4 weeks</td>
<td>8 weeks and at least 16 weeks after first dose. Minimum age for the final dose is 24 weeks.</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>6 weeks Maximum age for first dose is 14 weeks, 6 days</td>
<td></td>
<td>4 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Maximum age for final dose is 8 months, 0 days.</td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, and acellular pertussis</td>
<td>6 weeks</td>
<td></td>
<td>4 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No further doses needed if first dose was administered at age 15 months or older.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4 weeks if first dose was administered before the 1st birthday.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8 weeks (as final dose) if first dose was administered at age 12 through 14 months.</td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b</td>
<td>6 weeks</td>
<td></td>
<td>No further doses needed if first dose was administered at age 15 months or older.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4 weeks if current age is younger than 12 months and first dose was administered at younger than age 7 months and at least 1 previous dose was PRP-T (ActHib, Pentacel, Hibrix) or unknown.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8 weeks and age 12 through 59 months (as final dose) if current age is younger than 12 months and first dose was administered at age 7 through 11 months; OR if current age is 12 through 59 months and first dose was administered before the 1st birthday and second dose administered at younger than 15 months; OR if both doses were PRP-OMP (PedvaxHIB, Comvax) and were administered before the 1st birthday.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before the 1st birthday.</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td>6 weeks</td>
<td></td>
<td>No further doses needed for healthy children if previous dose was administered at age 24 months or older.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4 weeks if current age is younger than 12 months and previous dose was administered at &lt;7 months old.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8 weeks (as final dose for healthy children) if previous dose was administered between 7–11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was given before age 12 months.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age.</td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>6 weeks</td>
<td></td>
<td>4 weeks</td>
<td>6 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>if current age is &lt; 4 years. if current age is &lt; 4 years.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4 weeks if current age is 4 years or older. 6 months (as final dose) if current age is 4 years or older.</td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>12 months</td>
<td></td>
<td>4 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6 months (as final dose) if current age is 4 years or older.</td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>12 months</td>
<td></td>
<td>3 months</td>
<td>3 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>if younger than age 13 years.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4 weeks if age 13 years or older.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8 weeks and at least 16 weeks after first dose.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6 months if first dose of DTaP/DT was administered before the 1st birthday. 6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the 1st birthday.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Routine dosing intervals are recommended.</td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>2 months MenACWY-CRM 9 months MenACWY-D</td>
<td></td>
<td>8 weeks</td>
<td>See Notes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>See Notes</td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td>9 years</td>
<td></td>
<td>Routine dosing intervals are recommended.</td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>N/A</td>
<td></td>
<td>6 months</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>N/A</td>
<td></td>
<td>6 months</td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>N/A</td>
<td></td>
<td>4 weeks</td>
<td>6 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A fourth dose of IPV is indicated if all previous doses were administered at &lt;4 years or if the third dose was administered &lt;6 months after the previous dose.</td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>N/A</td>
<td></td>
<td>4 weeks</td>
<td>8 weeks and at least 16 weeks after first dose.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6 months if first dose of DTaP/DT was administered before the 1st birthday.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Routine dosing intervals are recommended.</td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>N/A</td>
<td></td>
<td>3 months if younger than age 13 years. 4 weeks if age 13 years or older.</td>
<td></td>
</tr>
<tr>
<td>VACCINE</td>
<td>Pregnancy</td>
<td>Immunocompromised status (excluding HIV infection)</td>
<td>HIV infection CD4+ count^1</td>
<td>Kidney failure, end-stage renal disease, or on hemodialysis</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------</td>
<td>---------------------------------------------------</td>
<td>---------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, &amp; acellular pertussis (DTaP)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenza type b</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (IIV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (LAIV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, &amp; acellular pertussis (Tdap)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal polysaccharide</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Vaccination according to the routine schedule recommended
Recommended for persons with an additional risk factor for which the vaccine would be indicated
Vaccination is recommended, and additional doses may be necessary based on medical condition. See Notes.
Not recommended/contraindicated—vaccine should not be administered
Precaution—vaccine might be indicated if benefit of protection outweighs risk of adverse reaction
Delay vaccination until after pregnancy if vaccine indicated
No recommendation/not applicable

1 For additional information regarding HIV laboratory parameters and use of live vaccines, see the General Best Practice Guidelines for Immunization, “Altered Immunocompetence,” at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html and Table 4-1 (footnote D) at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html.

2 Severe Combined Immunodeficiency

3 LAIV contraindicated for children 2–4 years of age with asthma or wheezing during the preceding 12 months.
For vaccine recommendations for persons 19 years of age or older, see the Recommended Adult Immunization Schedule.

**Additional information**

- Consult relevant ACIP statements for detailed recommendations at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
- For information on contraindications and precautions for the use of a vaccine, consult the General Best Practice Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html and relevant ACIP statements at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
- For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥4 months are determined by calendar months.
- Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
- Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3-1, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
- Information on travel vaccine requirements and recommendations is available at www.cdc.gov/travel/.
- For information regarding vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department.
- The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine child and adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information, see www.hrsa.gov/vaccinecompensation/index.html.

### Diphtheria, tetanus, and pertussis (DTaP) vaccination (minimum age: 6 weeks [4 years for Kinrix or Quadracel])

#### Routine vaccination
- 5-dose series at 2, 4, 6, 15–18 months, 4–6 years
  - **Prospectively:** Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3.
  - **Retrospectively:** A 4th dose that was inadvertently administered as early as 12 months may be counted if at least 4 months have elapsed since dose 3.

#### Catch-up vaccination
- Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3.
- For other catch-up guidance, see Table 2.

### Haemophilus influenzae type b vaccination (minimum age: 6 weeks)

#### Routine vaccination
- ActHIB, Hiberix, or Pentacel: 4-dose series at 2, 4, 6, 12–15 months
- PedvaxHIB: 3-dose series at 2, 4, 12–15 months

#### Catch-up vaccination
- **Dose 1 at 7–11 months:** Administer dose 2 at least 4 weeks later and dose 3 (final dose) at 12–15 months or 8 weeks after dose 2 (whichever is later).
- **Dose 1 at 12–14 months:** Administer dose 2 (final dose) at least 8 weeks after dose 1.
- **Dose 1 before 12 months and dose 2 before 15 months:** Administer dose 3 (final dose) 8 weeks after dose 2.
- **2 doses of PedvaxHIB before 12 months:** Administer dose 3 (final dose) at 12–59 months and at least 8 weeks after dose 2.
- **Unvaccinated at 15–59 months:** 1 dose
- **Previously unvaccinated children age 60 months or older** who are not considered high risk do not require catch-up vaccination.
- For other catch-up guidance, see Table 2.

### Special situations

- **Chemotherapy or radiation treatment:**
  - 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
  - Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
  - 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
  - Retrospectively: - 1 dose
  - Prospectively: - 1 dose
  - Previously unvaccinated age 5 years or older

- **Hematoopoietic stem cell transplant (HSCT):**
  - 3-dose series 4 weeks apart starting 6 to 12 months after successful transplant, regardless of Hib vaccination history

- **Anatomic or functional asplenia (including sickle cell disease):**
  - 12–59 months
  - Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
  - 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
  - _Unvaccinated* persons age 5 years or older_
    - 1 dose
  - _Unvaccinated* persons age 15 months or older_
    - 1 dose (preferably at least 14 days before procedure)

- **HIV infection:**
  - 12–59 months
  - Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
  - 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
  - _Unvaccinated* persons age 5–18 years_
    - 1 dose

- **Immunoglobulin deficiency, early component complement deficiency:**
  - 12–59 months
  - Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
  - 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

*Unvaccinated* = Less than routine series (through 14 months) OR no doses (15 months or older)
Hepatitis A vaccination
(minimum age: 12 months for routine vaccination)

**Routine vaccination**
- 2-dose series (minimum interval: 6 months) beginning at age 12 months

**Catch-up vaccination**
- Unvaccinated persons through 18 years should complete a 2-dose series (minimum interval: 6 months).
- Persons who previously received 1 dose at age 12 months or older should receive dose 2 at least 6 months after dose 1.

**Adolescents**
- 18 years and older may receive the combined HepA and HepB vaccine, Twinrix®, as a 3-dose series (0, 1, and 6 months) or 4-dose series (0, 7, and 21–30 days, followed by a dose at 12 months).

**International travel**
- Persons traveling to or working in countries with high or intermediate endemic hepatitis A (www.cdc.gov/travel/):
  - Infants age 6–11 months: 1 dose before departure; revaccinate with 2 doses, separated by at least 6 months, between 12 and 23 months of age
  - Unvaccinated age 12 months and older: Administer dose 1 as soon as travel is considered.

Hepatitis B vaccination
(minimum age: birth)

**Birth dose (monovalent HepB vaccine only)**
- **Mother is HBsAg-negative:** 1 dose within 24 hours of birth for all medically stable infants ≥2,000 grams. Infants <2,000 grams: Administer 1 dose at chronological age 1 month or hospital discharge.
- **Mother is HBsAg-positive:**
  - Administer HepB vaccine and hepatitis B immune globulin (HBIG) (in separate limbs) within 12 hours of birth, regardless of birth weight. For infants <2,000 grams, administer an additional dose beginning at age 1 month.
  - Test for HBsAg and anti-HBs at age 9–12 months. If HepB series is delayed, test 1–2 months after final dose.
- **Mother’s HBsAg status is unknown:**
  - Administer HepB vaccine within 12 hours of birth, regardless of birth weight.
  - For infants <2,000 grams, administer HBIG in addition to HepB vaccine (in separate limbs) within 12 hours of birth. Administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.
  - Determine mother’s HBsAg status as soon as possible. If mother is HBsAg-positive, administer HBIG to infants ≥2,000 grams as soon as possible, but no later than 7 days of age.

**Routine series**
- 3-dose series at 0, 1–2, 6–18 months (use monovalent HepB vaccine for doses administered before age 6 weeks)

**Special situations**
- Infants who did not receive a birth dose should begin the series as soon as feasible (see Table 2).
- Administration of 4 doses is permitted when a combination vaccine containing HepB is used after the birth dose.
- **Minimum age for the final (3rd or 4th) dose:** 24 weeks
- **Minimum intervals:** dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 8 weeks / dose 1 to dose 3: 16 weeks (when 4 doses are administered, substitute “dose 4” for “dose 3” in these calculations)

**Catch-up vaccination**
- Unvaccinated persons should complete a 3-dose series at 0, 1–2, 6 months.
- Adolescents age 11–15 years may use an alternative 2-dose schedule with at least 4 months between doses (adult formulation Recombivax HB only).
- Adolescents 18 years and older may receive a 2-dose series of HepB (Heplisav-B®) at least 4 weeks apart.

**Infants age 6–11 months**
- Administer 1 dose within 12 hours of birth, regardless of birth weight. For infants <2,000 grams, administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.

**Notes**
- For infants born to HBsAg-positive mothers
- For other catch-up guidance, see Table 2.

**Human papillomavirus vaccination**
(minimum age: 9 years)

**Routine and catch-up vaccination**
- HPV vaccination routinely recommended at age 11–12 years (can start at age 9 years) and catch-up HPV vaccination recommended for all persons through age 18 years if not adequately vaccinated.
- 2- or 3-dose series depending on age at initial vaccination:
  - Age 9 through 14 years at initial vaccination: 2-dose series at 0, 6–12 months (minimum interval: 5 months; repeat dose if administered too soon)
  - Age 15 years or older at initial vaccination: 3-dose series at 0, 1–2 months, 6 months (minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 12 weeks / dose 1 to dose 3: 5 months; repeat dose if administered too soon)
  - If completed valid vaccination series with any HPV vaccine, no additional doses needed

**Special situations**
- Immunocompromising conditions, including HIV infection:
  - 3-dose series as above
- History of sexual abuse or assault: Start at age 9 years.
- Pregnancy: HPV vaccination not recommended until after pregnancy; no intervention needed if vaccinated while pregnant; pregnancy testing not needed before vaccination

Influenza vaccination
(minimum age: 6 months [IIV], 2 years [LAIV], 18 years [recombinant influenza vaccine, RIV])

**Routine vaccination**
- Use any influenza vaccine appropriate for age and health status annually:
  - 2 doses, separated by at least 4 weeks, for children age 6 months–8 years who have received fewer than 2 influenza vaccine doses before July 1, 2019, or whose influenza vaccination history is unknown (administer dose 2 even if the child turns 9 between receipt of dose 1 and dose 2)
  - 1 dose for children age 6 months–8 years who have received at least 2 influenza vaccine doses before July 1, 2019
  - 1 dose for all persons age 9 years and older
- For the 2020–21 season, see the 2020–21 ACIP influenza vaccine recommendations

**Special situations**
- Egg allergy, hives only: Any influenza vaccine appropriate for age and health status annually
- Egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress, need for emergency medical services or epinephrine): Any influenza vaccine appropriate for age and health status annually in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions
- LAIV should not be used in persons with the following conditions or situations:
  - History of severe allergic reaction to a previous dose of any influenza vaccine or to any vaccine component (excluding egg, see details above)
  - Receiving aspirin or salicylate-containing medications
  - Age 2–4 years with history of asthma or wheezing
  - Immunocompromised due to any cause (including medications and HIV infection)
  - Anatomic or functional asplenia
  - Cochlear implant
  - Cerebrospinal fluid-oropharyngeal communication
  - Close contacts or caregivers of severely immunosuppressed persons who require a protected environment
  - Pregnancy
  - Received influenza antiviral medications within the previous 48 hours
Travel in countries with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during the Hajj (www.cdc.gov/travel/):
- Children less than age 24 months:
  - Menevo (age 2–23 months):
    - Dose 1 at 8 weeks: 4-dose series at 2, 4, 6, 12 months
    - Dose 1 at 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)
  - Menactra (age 9–23 months):
    - 2-dose series (dose 2 at least 12 weeks after dose 1; dose 2 may be administered as early as 8 weeks after dose 1 in travelers)
- Children age 2 years or older: 1 dose Menevo or Menactra

First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) or military recruits:
- 1 dose Menevo or Menactra

Adolescent vaccination of children who received MenACWY prior to age 10 years:
- Children for whom boosters are recommended because of an ongoing increased risk of meningococcal disease (e.g., those with complement deficiency, HIV, or asplenia): Follow the booster schedule for persons at increased risk (see below).
- Children for whom boosters are not recommended (e.g., those who received a single dose for travel to a country where meningococcal disease is endemic): Administer MenACWY according to the recommended adolescent schedule with dose 1 at age 11–12 years and dose 2 at age 16 years.

**Notes**

- Measles, mumps, and rubella vaccination (minimum age: 12 months for routine vaccination)
- Routine vaccination:
  - 2-dose series at 12–15 months, 4–6 years
  - Dose 2 may be administered as early as 4 weeks after dose 1.
- Catch-up vaccination:
  - Unvaccinated children and adolescents: 2-dose series at least 4 weeks apart
  - The maximum age for use of MMRV is 12 years.

**Special situations**

- **International travel**
  - Infants age 6–11 months: 1 dose before departure; revaccinate with 2-dose series with dose 1 at 12–15 months (12 months for children in high-risk areas) and dose 2 as early as 4 weeks later.
  - Unvaccinated children age 12 months and older: 2-dose series at least 4 weeks apart before departure

- Meningococcal serogroup A,C,W,Y vaccination (minimum age: 2 months [MenACWY CRM, Menevo], 9 months [MenACWY-D, Menactra])

  **Routine vaccination**
  - 2-dose series at 11–12 years, 16 years

  **Catch-up vaccination**
  - Age 13–15 years: 1 dose now and booster at age 16–18 years (minimum interval: 8 weeks)
  - Age 16–18 years: 1 dose

  **Special situations**

  - **Anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:**
    - Menevo:
      - Dose 1 at age 8 weeks: 4-dose series at 2, 4, 6, 12 months
      - Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)
      - Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart
    - Menactra:
      - Persistent complement component deficiency or complement inhibitor use:
        - Age 9–23 months: 2-dose series at least 12 weeks apart
        - Age 24 months or older: 2-dose series at least 8 weeks apart
      - **Anatomic or functional asplenia, sickle cell disease, or HIV infection:**
        - Age 9–23 months: Not recommended
        - Age 24 months or older: 2-dose series at least 8 weeks apart
        - **Menactra** must be administered at least 4 weeks after completion of PCV13 series.

- Pneumococcal vaccination (minimum age: 6 weeks [PCV13], 2 years [PPSV23])

  **Routine vaccination with PCV13**
  - 4-dose series at 2, 4, 6, 12–15 months

  **Catch-up vaccination with PCV13**
  - 1 dose for healthy children age 24–59 months with any incomplete* PCV13 series
  - For other catch-up guidance, see Table 2.

  **Special situations**

  - **High-risk conditions below:** When both PCV13 and PPSV23 are indicated, administer PCV13 first. PCV13 and PPSV23 should not be administered during the same visit.

  **Chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure), chronic lung disease (including asthma treated with high-dose, oral corticosteroids), diabetes mellitus:**
  - Age 2–5 years
    - Any incomplete* series with:
      - 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)
      - Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
      - No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose)
  - Age 6–18 years
    - No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose)

  **Cerebrospinal fluid leak, cochlear implant:**
  - Age 2–5 years
    - Any incomplete* series with:
      - 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)
      - Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
      - No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose)
  - Age 6–18 years
    - No history of either PCV13 or PPSV23: 1 dose PCV13, 1 dose PPSV23 at least 8 weeks later
    - Any PCV13 but no PPSV23: 1 dose PCV13, 1 dose PPSV23 at least 8 weeks after the most recent dose of PCV13
    - PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent dose of PPSV23

- Meningococcal serogroup B vaccination (minimum age: 10 years [MenB-4C, Bexsero; MenB-FHbp, Trumenba])

  **Shared clinical decision-making**
  - Adolescents not at increased risk age 16–23 years (preferred age 16–18 years) based on shared clinical decision-making:
    - Bexsero: 2-dose series at least 1 month apart
    - Trumenba: 2-dose series at least 6 months apart; if dose 2 is administered earlier than 6 months, administer a 3rd dose at least 4 months after dose 2.

  **Special situations**

  - **Anatomic or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:**
    - Bexsero: 2-dose series at least 1 month apart
    - Trumenba: 3-dose series at 0, 1–2, 6 months

- Bexsero and Trumenba are not interchangeable; the same product should be used for all doses in a series. For MenB booster dose recommendations for groups listed under “Special situations” and in an outbreak setting and for additional meningococcal vaccination information, see www.cdc.gov/vaccines/acip/recommendations.html and www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html.
Sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiency; HIV infection; chronic renal failure; nephrotic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with treatment with immunosuppressive drugs or radiation therapy; solid organ transplantation; multiple myeloma:

**Age 2–5 years**
- Any incomplete* series with:
  - 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)
  - Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
- No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose) and a 2nd dose of PPSV23 5 years later
- No history of either PCV13 or PPSV23: 1 dose PCV13, 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23)
- Any PCV13 but no PPSV23: 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after the most recent dose of PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23)
- PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent PPSV23 dose and a 2nd dose of PPSV23 administered 5 years after dose 1 of PPSV23 and at least 8 weeks after a dose of PCV13

**Chronic liver disease, alcoholism:**

**Age 6–18 years**
- No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose)

*Incomplete series = Not having received all doses in either the recommended series or an age-appropriate catch-up series. See Tables 8, 9, and 11 in the ACIP pneumococcal vaccine recommendations at www.cdc.gov/mmwr/pdf/rr/rr5911.pdf for complete schedule details.

**Poliovirus vaccination**

**(minimum age: 6 weeks)**

**Routine vaccination**
- 4-dose series at ages 2, 4, 6–18 months, 4–6 years; administer the final dose at or after age 4 years and at least 6 months after the previous dose.
- 4 or more doses of IPV can be administered before age 4 years when a combination vaccine containing IPV is used. However, a dose is still recommended at or after age 4 years and at least 6 months after the previous dose.

**Catch-up vaccination**
- In the first 6 months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak.
- IPV is not routinely recommended for U.S. residents 18 years and older.
- Series containing oral polio vaccine (OPV), either mixed OPV-IPV or OPV-only series:
  - Total number of doses needed to complete the series is the same as that recommended for the U.S. IPV schedule. See www.cdc.gov/mmwr/volumes/66/wr/mm6601a6.htm?s_cid=mm6601a6_w.
- Only trivalent OPV (TOPV) counts toward the U.S. vaccination requirements.
  - Doses of OPV administered before April 1, 2016, should be counted (unless specifically noted as administered during a campaign).
  - Doses of OPV administered on or after April 1, 2016, should not be counted.
  - For guidance to assess doses documented as “OPV,” see www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm?s_cid=mm6606a7_w.
- For other catch-up guidance, see Table 2.

**Rotavirus vaccination**

**(minimum age: 6 weeks)**

**Routine vaccination**
- **Rotarix:** 2-dose series at 2 and 4 months
- **RotaTeq:** 3-dose series at 2, 4, and 6 months
- If any dose in the series is either RotaTeq or unknown, default to 3-dose series.

**Catch-up vaccination**
- Do not start the series on or after age 15 weeks, 0 days.
- The maximum age for the final dose is 8 months, 0 days.
- For other catch-up guidance, see Table 2.

**Varicella vaccination**

**(minimum age: 12 months)**

**Routine vaccination**
- 2-dose series at 12–15 months, 4–6 years
- Dose 2 may be administered as early as 3 months after dose 1 (a dose administered after a 4-week interval may be counted).

**Catch-up vaccination**
- Ensure persons age 7–18 years without evidence of immunity (see www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2-dose series:
  - Age 7–12 years: routine interval: 3 months (a dose administered after a 4-week interval may be counted)
  - Age 13 years and older: routine interval: 4–8 weeks (minimum interval: 4 weeks)
- The maximum age for use of MMRV is 12 years.

**Tetanus, diphtheria, and pertussis (Tdap) vaccination**

**(minimum age: 11 years for routine vaccination, 7 years for catch-up vaccination)**

**Routine vaccination**
- **Adolescents age 11–12 years:** 1 dose Tdap
- **Pregnancy:** 1 dose Tdap during each pregnancy, preferably in early part of gestational weeks 27–36
- Tdap may be administered regardless of the interval since the last tetanus- and diphtheria-toxoid-containing vaccine.

**Catch-up vaccination**
- **Adolescents age 13–18 years who have not received Tdap:**
  - 1 dose Tdap, then Td or Tdap booster every 10 years
- **Persons age 7–18 years not fully vaccinated** with DTAp:
  - 1 dose Tdap as part of the catch-up series (preferably the first dose); if additional doses are needed, use Td or Tdap.
- **Tdap administered at 7–10 years:**
  - **Children age 7–9 years** who receive Tdap should receive the routine Tdap dose at age 11–12 years.
  - **Children age 10 years** who receive Tdap do not need to receive the routine Tdap dose at age 11–12 years.
- **DTaP inadvertently administered at or after age 7 years:**
  - **Children age 7–9 years:** DTAp may count as part of catch-up series. Routine Tdap dose at age 11–12 years should be administered.
  - **Children age 10–18 years:** Count dose of DTaP as the adolescent Tdap booster.
- For other catch-up guidance, see Table 2.
- For information on use of Tdap or Td as tetanus prophylaxis in wound management, see www.cdc.gov/mmwr/volumes/67/rr/rr6702a1.htm.

*Fully vaccinated = 5 valid doses of DTaP OR 4 valid doses of DTaP if dose 4 was administered at age 4 years or older.*